- C4 Imaging announces that Isoray Medical (NYSEMKT:ISR) has received U.S. FDA clearance for the use of C4 Imaging’s Sirius positive-signal MRI markers with Isoray’s Cesium-131, brachytherapy seeds.
- Isoray is the world’s only producer of Cesium-131, commercially known as Cesium Blu™, brachytherapy seeds.
- This combination will benefit the innovative technology and proprietary isotope to achieve new strides in the ongoing fight against prostate cancer.
- “Sirius MRI Markers will enable Isoray’s customers to fully utilize the benefits of MRI seed localization.” said Andrew Bright, President and CEO of C4 Imaging.
- ISR +69.81% AH to $0.90.
IsoRay rallies on FDA clearance for use of C4 Imaging's MRI markers
Recommended For You
About CATX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CATX | - | - |
Perspective Therapeutics, Inc. |